Impact of SAfinamide on Depressive Symptoms in Parkinson's Disease Patients (SADness-PD Study): A Multicenter Retrospective Study
Esteban Peña,Carmen Borrué,Marina Mata,Juan Carlos Martínez-Castrillo,Araceli Alonso-Canovas,Juan Luis Chico,Lydia López-Manzanares,Marcos Llanero,Jaime Herreros-Rodríguez,Alberto Esquivel,Teresa Maycas-Cepeda,Cristina Ruiz-Huete +11 more
Reads0
Chats0
TLDR
In this paper, the effects of safinamide on depression, motor symptoms, and the serotonin syndrome related to its co-administration with antidepressants in patients with Parkinson's disease (PD) were assessed.Abstract:
Background: We aimed to assess the effects of safinamide on depression, motor symptoms, and the serotonin syndrome related to its co-administration with antidepressants in patients with Parkinson’s disease (PD). Methods: We retrospectively analyzed the data of patients at 1 and 3 months of follow-up compared to baseline. Results: n = 82 (safinamide 50 mg = 22, 100 mg = 60, with antidepressants = 44). First, we found improvement in depression (Hamilton Depression Rating Scale: −6 ± 5.10 at 1 month and −7.27 ± 5.10 at 3 months, p < 0.0001; Patient Global Impression of Improvement Scale: 60.3% and 69.5% of patients at 1 and 3 months reported some improvement). Second, safinamide improved the daily life activities and motor symptoms/motor complications (Unified Parkinson’s Disease Rating Scale (UPDRS-II): −2.51 ± 6.30 and −2.47 ± 6.11 at 1 and 3 months, p < 0.0001; III: −3.58 ± 8.68 and −4.03 ± 8.95 at 1 and 3 months, p < 0.0001; IV: −0.61 ± 2.61 and −0.8 ± 2.53 at 1 and 3 months, p < 0.0001). Third, 7.31% and 8.53% of patients developed non-severe adverse events related to safinamide at 1 and 3 months. Serotonin syndrome was not observed in the patients treated with antidepressants; some isolated serotonin syndrome symptoms were reported. Conclusions: Safinamide could be useful for treating depression in PD; it was effective for motor symptoms and motor complications and safe even when co-administered with antidepressants.read more
Citations
More filters
Journal ArticleDOI
The neuropsychiatry of Parkinson's disease: advances and challenges
TL;DR: In people with Parkinson's disease, neuropsychiatric signs and symptoms are common throughout the disease course and their presentation can be similar to, or distinct from, their counterparts in the general population as mentioned in this paper .
Journal ArticleDOI
The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature.
TL;DR: Safinamide has been used for fluctuating Parkinson's disease (PD) as add-on therapy to levodopa regimens for the management of ‘off’ episodes as mentioned in this paper.
Journal ArticleDOI
Silibinin ameliorates depression/anxiety-like behaviors of Parkinson's disease mouse model and is associated with attenuated STING-IRF3-IFN-β pathway activation and neuroinflammation.
Xiumin Liu,Wenhui Chen,Chenkang Wang,Weiwei Liu,Toshihiko Hayashi,Kazunori Mizuno,Shunji Hattori,Hitomi Fujisaki,Takashi Ikejima +8 more
TL;DR: In this paper, the authors reported that silibinin showed anti-depressant and anti-anxiety effects on 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced model mice with Parkinson's disease.
Journal ArticleDOI
Present and Future of Parkinson’s Disease in Spain: PARKINSON-2030 Delphi Project
Diego Santos García,Marta Blázquez-Estrada,Matilde Calopa,Francisco Escamilla-Sevilla,E. Freire,Pedro J. Garcia Ruiz,Francisco Grandas,Jaime Kulisevsky,Lydia López-Manzanares,Juan Carlos Martínez Castrillo,P. Mir,P. Mir,Javier Pagonabarraga,Francisco Pérez-Errazquin,José María Salom,Beatriz Tijero,Francesc Valldeoriola,Rosa Yañez,Arantxa Avilés,Maria-Rosario Luquin +19 more
TL;DR: The unmet needs in diagnosis and treatment are highlighted and how crucial it is to establish recommendations for future diagnostic and therapeutic management of PD.
Journal ArticleDOI
Effectiveness of Safinamide over Mood in Parkinson's Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR.
Carmen M. Labandeira,Maria G. Alonso Losada,Rosa Yáñez Baña,Maria Icíar Cimas Hernando,Iria Cabo López,Jose Manuel Paz González,Maria José Gonzalez Palmás,Cristina Martínez Miró,Diego Santos García +8 more
TL;DR: The SAFINON MOTOR study as mentioned in this paper showed that SAFINamide improves mood in patients with Parkinson's disease at 6 months by reducing the BDI-II (Beck Depression Inventory-II), NMSS mood/apathy domain, and PDQ-39 (Parkinson’s Disease Questionnaire-39) emotional well-being domain.
References
More filters
Journal ArticleDOI
MDS clinical diagnostic criteria for Parkinson's disease
Ronald B. Postuma,Daniela Berg,Matthew B. Stern,Werner Poewe,C. Warren Olanow,Wolfgang H. Oertel,Jose A. Obeso,Kenneth Marek,Irene Litvan,Anthony E. Lang,Glenda M. Halliday,Christopher G. Goetz,Thomas Gasser,Bruno Dubois,Piu Chan,Bastiaan R. Bloem,Charles H. Adler,Guenther Deuschl +17 more
TL;DR: The Movement Disorder Society PD Criteria retain motor parkinsonism as the core feature of the disease, defined as bradykinesia plus rest tremor or rigidity, and two levels of certainty are delineated: clinically established PD and probable PD.
Journal ArticleDOI
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
TL;DR: A systematic review of studies reporting LEDs yielded a standardized LED for each drug, providing a useful tool to express dose intensity of different antiparkinsonian drug regimens on a single scale.
Journal ArticleDOI
Depression in Parkinson disease—epidemiology, mechanisms and management
TL;DR: The frequency and course of depression in patients with Parkinson disease is described, the mechanisms that underlie depression in this disease are discussed, and the management strategies for these patients are highlighted.
Journal ArticleDOI
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Paolo Barone,Werner Poewe,Stefan Albrecht,C. Debieuvre,Dan Massey,Olivier Rascol,Eduardo Tolosa,Daniel Weintraub,Daniel Weintraub +8 more
TL;DR: Pramipexole improved depressive symptoms in patients with Parkinson's disease, mainly through a direct antidepressant effect.
Journal ArticleDOI
Glutamatergic Modulators: The Future of Treating Mood Disorders?
Carlos A. Zarate,Rodrigo Machado-Vieira,Ioline D. Henter,Lobna Ibrahim,Nancy Diazgranados,Giacomo Salvadore +5 more
TL;DR: Evidence confirming the role of the glutamatergic modulators riluzole and ketamine as proof-of-concept agents in this system holds considerable promise for developing the next generation of novel therapeutics for the treatment of bipolar disorder and major depressive disorder.